Cargando…

The Biology and Therapeutic Potential of the Src-YAP Axis in Non-Small Cell Lung Cancer (NSCLC)

Detalles Bibliográficos
Autores principales:	Papavassiliou, Kostas A., Papavassiliou, Athanasios G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777266/ https://www.ncbi.nlm.nih.gov/pubmed/36551659 http://dx.doi.org/10.3390/cancers14246178

Ejemplares similares

Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks
por: Stravopodis, Dimitrios J., et al.
Publicado: (2023)

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Targeting the YAP/TAZ mechanotransducers in solid tumour therapeutics
por: Gargalionis, Antonios N., et al.
Publicado: (2023)

Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives
por: Gargalionis, Antonios N., et al.
Publicado: (2023)

Lung Cancer through Transcription Factors
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Malignant circuits: Novel therapeutic opportunities in neuro‐oncology
por: Papavassiliou, Kostas A., et al.
Publicado: (2021)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Polycystins, mechanotransduction and cancer development
por: Papavassiliou, Kostas A., et al.
Publicado: (2022)

G6PD and chloroquine: Selecting the treatment against SARS‐CoV‐2?
por: Kassi, Eva N., et al.
Publicado: (2020)

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?
por: Papavassiliou, Kostas A., et al.
Publicado: (2021)

Targeting STAT3 Signaling Pathway in Colorectal Cancer
por: Gargalionis, Antonios N., et al.
Publicado: (2021)

Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment
por: Piperi, Christina, et al.
Publicado: (2019)

Defective Anti-oxidant System: An Aggravating Factor for COVID-19 Patients Outcome?
por: Kassi, Eva N., et al.
Publicado: (2020)

Complexity in cancer biology: is systems biology the answer?
por: Koutsogiannouli, Evangelia, et al.
Publicado: (2013)

Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity
por: Markouli, Mariam, et al.
Publicado: (2021)

mTOR Signaling Components in Tumor Mechanobiology
por: Gargalionis, Antonios N., et al.
Publicado: (2022)

Crosstalk of Epigenetic and Metabolic Signaling Underpinning Glioblastoma Pathogenesis
por: Markouli, Mariam, et al.
Publicado: (2022)

Solid Cancers and Rheumatoid Arthritis
por: Kalliolias, George D., et al.
Publicado: (2023)

The Molecular Basis of Retinoids’ Use in Breast Cancer Chemoprevention
por: Karamouzis, Michalis V., et al.
Publicado: (2007)

Notching up a new therapeutic strategy for Non-Small Cell Lung Carcinoma (NSCLC)
por: Maraver, Antonio, et al.
Publicado: (2012)

CXCR4/CXCL12 Axis in Non Small Cell Lung Cancer (NSCLC) Pathologic Roles and Therapeutic Potential
por: Wald, Ori, et al.
Publicado: (2013)

Polycystins and mechanotransduction in bone
por: Gargalionis, Antonios N., et al.
Publicado: (2017)

The Multifaceted Output of c-Jun Biological Activity: Focus at the Junction of CD8 T Cell Activation and Exhaustion
por: Papavassiliou, Athanasios G., et al.
Publicado: (2020)

Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors
por: Sarantis, Panagiotis, et al.
Publicado: (2022)

Vitamin D affects glucocorticoid action in target cells
por: Kassi, Eva, et al.
Publicado: (2016)

A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma
por: Sun, Jingya, et al.
Publicado: (2018)

Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives
por: Koustas, Evangelos, et al.
Publicado: (2022)

Mechanosignalling in tumour progression
por: Gargalionis, Antonios N., et al.
Publicado: (2017)

SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC
por: Yuan, Man, et al.
Publicado: (2019)

A set of sum rules for anomalous gauge boson couplings
por: Papavassiliou, Joannis, et al.
Publicado: (1998)

Probing the $WW \gamma$ vertex at hadron colliders
por: Papavassiliou, Joannis, et al.
Publicado: (1999)

The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL
por: Simatou, Aristofania, et al.
Publicado: (2020)

Polycystin‐1 and hydrostatic pressure are implicated in glioblastoma pathogenesis in vitro
por: Zoi, Ilianna, et al.
Publicado: (2022)

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
por: Vallilas, Christos, et al.
Publicado: (2021)

The potential of Src inhibitors
por: Elias, Daniel, et al.
Publicado: (2015)

The glucocorticoid receptor signalling in breast cancer
por: Moutsatsou, Paraskevi, et al.
Publicado: (2008)

SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis
por: Lamar, John M., et al.
Publicado: (2019)

Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: Parums, Dinah V.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4q7q4urefvl1b0o4csgh0lifum